Jeanny B. Aragon-Ching, MD of the Inova Schar Cancer Institute has co-authored a groundbreaking bladder cancer research paper just published in the New England Journal of Medicine.
The large phase III clinical study showed that the addition of immunotherapy with Avelumab (Bavencio) increased the duration of overall survival by almost 50% in patients when given after chemotherapy in patients with locally advanced bladder cancer.
This practice-changing study showed how the addition of immunotherapy can have a dramatic impact on the lives of patients with certain cancers.
Leesburg, VA — Inova Loudoun Hospital Mobile Health Services will be providing countywide blood pressure…
Multiple Inova Hospitals Recognized Among Nation’s Best Fairfax, VA – Inova has been named the…
Devon Hawkins, MD, is a board‑certified general surgeon. Her clinical interests include minimally invasive and…
With new research published every week and the endless stream of nutrition information and opinions…
A major new study led by Wayne Batchelor, MD, an interventional cardiologist and President of…
Spring 2026 Safety Grade is a national recognition for commitment to patient safety Fairfax, VA…